Last reviewed · How we verify
Actidose Aqua
Actidose Aqua is an aqueous suspension of activated charcoal that binds toxins and drugs in the gastrointestinal tract to prevent their absorption.
Actidose Aqua is an aqueous suspension of activated charcoal that binds toxins and drugs in the gastrointestinal tract to prevent their absorption. Used for Acute poisoning and overdose (general antidote for various drugs and toxins), Gastrointestinal decontamination in emergency settings.
At a glance
| Generic name | Actidose Aqua |
|---|---|
| Also known as | Oral activated charcoal |
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Drug class | Adsorbent antidote |
| Modality | Small molecule |
| Therapeutic area | Toxicology / Poison Control |
| Phase | FDA-approved |
Mechanism of action
Activated charcoal is a highly porous form of carbon with a large surface area that adsorbs (binds) various drugs, toxins, and poisons within the stomach and intestines. By binding these substances, it prevents their systemic absorption and facilitates their elimination through feces. This mechanism makes it useful as a general antidote in acute poisoning and overdose situations.
Approved indications
- Acute poisoning and overdose (general antidote for various drugs and toxins)
- Gastrointestinal decontamination in emergency settings
Common side effects
- Black discoloration of stool
- Constipation
- Nausea
- Vomiting
- Abdominal discomfort
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Actidose Aqua CI brief — competitive landscape report
- Actidose Aqua updates RSS · CI watch RSS
- National Institute of Allergy and Infectious Diseases (NIAID) portfolio CI